David Taussig
YOU?
Author Swipe
View article: Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort Open
NCT02719574.
View article: Bone Marrow Failure in AML: Residual Neutrophils and Erythroblasts Are Derived By Differentiation from the AML
Bone Marrow Failure in AML: Residual Neutrophils and Erythroblasts Are Derived By Differentiation from the AML Open
Our previous work[1] suggests AML blocks the differentiation of normal haematopoietic stem cells (HSCs) leading to marrow failure. However, many patients do not have uniform pancytopenia where all differentiated blood cells are reduced e.g…
View article: Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapy
Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapy Open
Gilteritinib is the current standard of care for relapsed or refractory fms related receptor tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia in many countries, however outcomes for patients relapsing after contemporary first-line t…
View article: <scp>CREST</scp>‐<scp>UK</scp>: Real‐world effectiveness, safety and outpatient delivery of <scp>CPX</scp>‐351 for first‐line treatment of newly diagnosed therapy‐related <scp>AML</scp> and <scp>AML</scp> with myelodysplasia‐related changes in the <scp>UK</scp>
<span>CREST</span>‐<span>UK</span>: Real‐world effectiveness, safety and outpatient delivery of <span>CPX</span>‐351 for first‐line treatment of newly diagnosed therapy‐related <span>AML</span> and <span>AML</span> with myelodysplasia‐related changes in the <span>UK</span> Open
Summary Favourable outcomes with CPX‐351 versus conventional 7 + 3 were demonstrated in the pivotal phase III trial in adults aged 60–75 years with newly diagnosed, highrisk/secondary acute myeloid leukaemia (AML). As a complement to the c…
View article: Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AML
Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AML Open
Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can reduce or el…
View article: The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients
The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients Open
Introduction: t(6;9)(p23;q34.1)/DEK-NUP214 patients represent a discrete group of younger AML patients recognised as a separate disease entity in the World Health Organization classification of myeloid neoplasms. They typically display a d…
View article: EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia
EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia Open
Background: EP0042 was developed as an orally bioavailable potent inhibitor of FLT3 and Aurora kinases. Aurora kinases play an important role in acute myeloid leukemia (AML) and have been implicated in the development of resistance to FLT3…
View article: Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial Open
This is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in pa…
View article: Supplemental Figures from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Supplemental Figures from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients Open
Supplemental Figures
View article: Supplemental Table from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Supplemental Table from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients Open
Supplemental Table
View article: Supplemental Figures from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Supplemental Figures from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients Open
Supplemental Figures
View article: Supplemental Information from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Supplemental Information from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients Open
Supplemental Information
View article: Supplemental Information from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Supplemental Information from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients Open
Supplemental Information
View article: Supplemental Table from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Supplemental Table from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients Open
Supplemental Table
View article: Data from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Data from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients Open
Acute myeloid leukemia (AML) is sustained by a subpopulation of rare leukemia-initiating cells (LIC) detected in the xenograft assay by their capacity to self-renew and to generate non-LICs in vivo. The xenotransplantation model captures f…
View article: Data from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients
Data from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients Open
Acute myeloid leukemia (AML) is sustained by a subpopulation of rare leukemia-initiating cells (LIC) detected in the xenograft assay by their capacity to self-renew and to generate non-LICs in vivo. The xenotransplantation model captures f…
View article: A global study for acute myeloid leukemia with <i>RARG</i> rearrangement
A global study for acute myeloid leukemia with <i>RARG</i> rearrangement Open
Acute myeloid leukemia (AML) with retinoic acid receptor γ (RARG) rearrangement has clinical, morphologic, and immunophenotypic features similar to classic acute promyelocytic leukemia. However, AML with RARG rearrangement is insensitive t…
View article: Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory <i>IDH1</i>-mutated AML
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory <i>IDH1</i>-mutated AML Open
Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH1 inhibitor–naive patients with mIDH1R132 relapsed/refractory (R/R) acute myeloid leukemia (AML) re…
View article: Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes Open
Acute myeloid leukaemia (AML) patients harbouring certain chromosome abnormalities have particularly adverse prognosis. For these patients, targeted therapies have not yet made a significant clinical impact. To understand the molecular lan…
View article: Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months
Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months Open
We describe the longitudinal kinetics of the serological response in COVID-19 recovered patients over a period of 14 months. The antibody kinetics in a cohort of 192 recovered patients, including 66 patients for whom follow-up serum sample…
View article: Phosphonoacetate Modifications Enhance the Stability and Editing Yields of Guide RNAs for Cas9 Editors
Phosphonoacetate Modifications Enhance the Stability and Editing Yields of Guide RNAs for Cas9 Editors Open
CRISPR gene editing and control systems continue to emerge and inspire novel research and clinical applications. Advances in CRISPR performance such as optimizing the duration of activity in cells, tissues, and organisms, as well as limiti…
View article: Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial
Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial Open
The phase III MIRROS trial (NCT02545283) evaluated the efficacy and safety of the small-molecule MDM2 antagonist idasanutlin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Adults (N=447) with R/R AML…
View article: A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML Open
Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death-ligand 1 (PD-L1) inhibitor, combined with …
View article: Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service
Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service Open
Background Early data suggest that patients undergoing salvage chemotherapy for relapsed or refractory (R/R) acute myeloid leukaemia (AML) have poor outcomes if infected with SARS-CoV-2, and nosocomial transmission has been a major problem…
View article: Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service
Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service Open
Background Based on early evidence of a high rate of coronavirus mortality in patients with acute myeloid leukaemia (AML) undergoing intensive chemotherapy (IC), the national health service (NHS) in the United Kingdom temporarily made vene…
View article: The longitudinal kinetics of antibodies in COVID-19 recovered patients over 14 months
The longitudinal kinetics of antibodies in COVID-19 recovered patients over 14 months Open
Summary Here, we describe the longitudinal kinetics of the serological response in COVID-19 recovered patients over the period of 14 months. The antibody kinetics in a cohort of 200 recovered patients with 89 follow up samples at 2-4 visit…
View article: Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence
Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence Open
The specific niche adaptations that facilitate primary disease and Acute Lymphoblastic Leukaemia (ALL) survival after induction chemotherapy remain unclear. Here, we show that Bone Marrow (BM) adipocytes dynamically evolve during ALL patho…